Monkeypox virus-infected individuals mount comparable humoral immune responses as Smallpox-vaccinated individuals.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
23 Sep 2023
23 Sep 2023
Historique:
received:
12
01
2023
accepted:
11
09
2023
medline:
27
11
2023
pubmed:
24
9
2023
entrez:
23
9
2023
Statut:
epublish
Résumé
In early 2022, a cluster of monkeypox virus (MPXV) infection (mpox) cases were identified within the UK with no prior travel history to MPXV-endemic regions. Subsequently, case numbers exceeding 80,000 were reported worldwide, primarily affecting gay, bisexual, and other men who have sex with men (GBMSM). Public health agencies worldwide have offered the IMVANEX Smallpox vaccination to these individuals at high-risk to provide protection and limit the spread of MPXV. We have developed a comprehensive array of ELISAs to study poxvirus-induced antibodies, utilising 24 MPXV and 3 Vaccinia virus (VACV) recombinant antigens. Panels of serum samples from individuals with differing Smallpox-vaccine doses and those with prior MPXV infection were tested on these assays, where we observed that one dose of Smallpox vaccination induces a low number of antibodies to a limited number of MPXV antigens but increasing with further vaccination doses. MPXV infection induced similar antibody responses to diverse poxvirus antigens observed in Smallpox-vaccinated individuals. We identify MPXV A27 as a serological marker of MPXV-infection, whilst MPXV M1 (VACV L1) is likely IMVANEX-specific. Here, we demonstrate analogous humoral antigen recognition between both MPXV-infected or Smallpox-vaccinated individuals, with binding to diverse yet core set of poxvirus antigens, providing opportunities for future vaccine (e.g., mRNA) and therapeutic (e.g., mAbs) design.
Identifiants
pubmed: 37741831
doi: 10.1038/s41467-023-41587-x
pii: 10.1038/s41467-023-41587-x
pmc: PMC10517934
doi:
Substances chimiques
Smallpox Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5948Informations de copyright
© 2023. Crown.
Références
J Virol. 2022 Feb 9;96(3):e0150421
pubmed: 34851148
Front Immunol. 2011 Jun 14;2:21
pubmed: 22566811
Virology. 1990 Nov;179(1):247-66, 517-63
pubmed: 2219722
Nat Med. 2006 Nov;12(11):1310-5
pubmed: 17086190
J Virol. 1992 Jan;66(1):386-98
pubmed: 1727494
Virology. 2002 Jun 5;297(2):172-94
pubmed: 12083817
J Virol. 2008 Apr;82(7):3517-29
pubmed: 18199639
J Virol. 2005 Jun;79(12):7845-51
pubmed: 15919938
J Clin Virol. 2009 Apr;44(4):308-13
pubmed: 19243990
Emerg Infect Dis. 2006 Jan;12(1):134-7
pubmed: 16494730
Lancet Infect Dis. 2023 Mar;23(3):320-330
pubmed: 36356606
J Virol. 2000 Dec;74(24):11654-62
pubmed: 11090164
Euro Surveill. 2021 Aug;26(32):
pubmed: 34387184
Nat Med. 2003 Sep;9(9):1131-7
pubmed: 12925846
Clin Infect Dis. 2014 Jan;58(2):260-7
pubmed: 24158414
Virology. 2007 Sep 15;366(1):73-83
pubmed: 17507071
Emerg Infect Dis. 2007 Sep;13(9):1332-9
pubmed: 18252104
J Virol. 2006 Oct;80(19):9455-64
pubmed: 16973551
J Gen Virol. 2011 Sep;92(Pt 9):1971-1980
pubmed: 21715594
Signal Transduct Target Ther. 2023 Apr 28;8(1):172
pubmed: 37117161
Emerg Infect Dis. 2020 Apr;26(4):782-785
pubmed: 32023204
Microbiology (Reading). 2010 Mar;156(Pt 3):940-949
pubmed: 19942658
Euro Surveill. 2018 Sep;23(38):
pubmed: 30255836
J Virol. 2002 Oct;76(19):9575-87
pubmed: 12208937
Virology. 1986 Mar;149(2):174-89
pubmed: 3456179
J Med Virol. 2023 Jan;95(1):e28036
pubmed: 35906185
Virology. 2003 Feb 1;306(1):181-95
pubmed: 12620810
Am J Infect Control. 1982 May;10(2):53-9
pubmed: 7044193
Nature. 2004 Mar 11;428(6979):182-5
pubmed: 15014500
J Infect Dis. 2017 Dec 19;216(12):1505-1512
pubmed: 29029254
Virology. 2000 Jan 20;266(2):329-39
pubmed: 10639319
J Virol. 2013 Jan;87(2):900-11
pubmed: 23135728
Clin Vaccine Immunol. 2007 Oct;14(10):1318-27
pubmed: 17715329
PLoS One. 2010 Dec 30;5(12):e15547
pubmed: 21209900
J Virol. 2008 May;82(9):4205-14
pubmed: 18287241
J Virol. 2009 Feb;83(4):1546-54
pubmed: 19036815
Nat Med. 2023 Jan;29(1):270-278
pubmed: 36257333
Lancet Infect Dis. 2023 Sep;23(9):1042-1050
pubmed: 37336224
Nat Med. 2005 Jul;11(7):740-7
pubmed: 15951823
Proteomics. 2007 May;7(10):1678-86
pubmed: 17443847
Bull World Health Organ. 2003;81(10):762-7
pubmed: 14758439
Cell Host Microbe. 2022 Dec 14;30(12):1662-1670.e4
pubmed: 36463861
J Virol. 2007 Sep;81(17):8989-95
pubmed: 17581986
Emerg Infect Dis. 2008 Apr;14(4):592-9
pubmed: 18394277
Science. 2022 Nov 4;378(6619):560-565
pubmed: 36264825
PLoS One. 2013 Dec 03;8(12):e79953
pubmed: 24312452
Cell. 2016 Oct 20;167(3):684-694.e9
pubmed: 27768891
J Gen Virol. 2012 Oct;93(Pt 10):2098-2108
pubmed: 22791606
Am J Med. 2008 Dec;121(12):1058-64
pubmed: 19028201
J Virol. 2004 May;78(9):4433-43
pubmed: 15078924
J Virol. 2006 Sep;80(17):8763-77
pubmed: 16912323
Nat Med. 2022 Aug;28(8):1569-1572
pubmed: 35750157
Lancet Infect Dis. 2023 Jul;23(7):828-835
pubmed: 36924787
Clin Diagn Lab Immunol. 2005 Jul;12(7):867-72
pubmed: 16002637
Virology. 2004 Aug 1;325(2):425-31
pubmed: 15246280
Virus Res. 2022 Dec;322:198932
pubmed: 36165924
J Clin Microbiol. 2003 Sep;41(9):4068-70
pubmed: 12958227
Immunol Rev. 2008 Oct;225:96-113
pubmed: 18837778
mBio. 2022 Oct 31;13(6):e0286222
pubmed: 36314809
JAMA. 2003 Jul 2;290(1):23-4
pubmed: 12837700
Vaccine. 2011 Dec 30;29 Suppl 4:D49-53
pubmed: 22185833
Mol Ther Oncolytics. 2019 May 21;14:159-171
pubmed: 31236440